UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in ...

Ractigen’s small activating RNA (saRNA) therapy, RAG-01, designed to treat non-muscle invasive bladder cancer (NMIBC) has shown early promise in a Phase I trial. Data presented at the European ...

With its discovery of small molecules that activate RNA methylation, the biotech has broken new ground in epitranscriptomics. This breakthrough positions Chemestmed to advance candidates with the ...

UK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed up with the London-based startup to develop its small, activating ...

and their diversity of functions has led to the hypothesis that an "RNA world" may have preceded the evolution of DNA and proteins (Gilbert, 1986). Small interfering RNAs (siRNAs) are yet another ...

NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today ...